Dose intensity• Delays attributable to PCV toxicity: 45.6% of patients• Dose reduction: 21.1% of patients• ≥1 incomplete cycle or treatment discontinued: 38.6% of patientsToxicity, %:• Grade 3 anemia: 7.0• Grade 3 neutropenia: 10.5• Grade 3 thrombocytopenia: 28.1• Increased aminotransferase: 64.9• Low CD4 count: 31.6• Neurotoxicity: 59.6• Nausea: 70.2• Vomiting: 40.3 This evidence concerns the gene CD4 and anemia.